| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V40067-1mg |
≥99% | ￥900.00 |
货期：3-5天 | - | - | - | - |
|
V40067-5mg |
≥99% | ￥2310.00 |
货期：3-5天 | - | - | - | - |
|
V40067-10mg |
≥99% | ￥3300.00 |
货期：3-5天 | - | - | - | - |
|
V40067-25mg |
≥99% | ￥5280.00 |
货期：3-5天 | - | - | - | - |
|
V40067-50mg |
≥99% | ￥7260.00 |
货期：3-5天 | - | - | - | - |
|
V40067-100mg |
≥99% | ￥9790.00 |
货期：3-5天 | - | - | - | - |
|
V40067-200mg |
≥99% | ￥13200.00 |
货期：3-5天 | - | - | - | - |
|
| 体内研究： | Rabacfosadine (RAB) has substantial single-agent activity in dogs with lymphoma, and a different mechanism of action than Doxorubicin (DOX). Open-label, multicenter prospective clinical trial. Dogs receive alternating Rabacfosadine (1.0 mg/kg IV weeks 0, 6, 12) and Doxorubicin (30 mg/m2 IV weeks 3, 9, 15). Dogs that achieved complete response (CR) are followed by monthly evaluations. Complete clinicopathological evaluation and assessment of remission and adverse event (AEs) are performed every 21 days. Acute AEs, occurring within 21 days after administration of the first dose of each agent, are compared between Rabacfosadine and Doxorubicin in 46 dogs receiving at least 1 dose of each agent. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 溶解性： | DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京